Claritas Pharmaceuticals Inc CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

GREY:CLAZF - Post by User

Claritas Pharmaceuticals Inc > I forgot about this one.

<< Previous

Bullboard Posts

Next >>

Post by Dude51on Apr 28, 2020 1:41am

293 Views

Post# 30960592

I forgot about this one.

https://www.bnnbloomberg.ca/cbd-based-drug-for-juvenile-epilepsy-receives-fda-approval-1.1098333

What say you bashers? Please provide a link to non Fox website that supports anything that you spew.

This company is going to pop, T-1012 I think is link to Covid-19, why not, it could. GLTA

<< Previous

Bullboard Posts

Next >>

Bragg’s iGaming platform drops in Brazil